The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.

Unlike animals, plants do not possess an adaptive immune system with antibodies or T cells to fight viral infections. Instead ...

Before a prostate biopsy is performed, various preliminary screening procedures are typically conducted. These include a ...

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...

Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a ...

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 ...

Bioluminescent luciferase enzymes have historically been too dim to use as probes in living tissue. But recent advances have ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

There is an urgent need for precision immunotherapy strategies that simultaneously target both tumor cells and immune cells ...